Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base

Haque, Waqar; Verma, Vivek; Fakhreddine, Mohamad; Hatch, Sandra S.; Butler, E. Brian; Teh, Bin S.

doi:10.1016/j.ygyno.2016.10.033

Cited by 35 publications

(22 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Younger age has been shown to associate with more advanced disease ; node‐positivity and male gender also correlate with poorer prognosis . In this manner, consistent with other work, it is plausible that chemotherapy potentially may have been given to a “higher‐risk” population, and that there may be “true” benefits to adding chemotherapy .…”

Section: Discussionsupporting

confidence: 77%

Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

Older patients are at increased risk of toxicities from aggressive oncologic therapy and of nononcologic death. A meta‐analysis of non‐nasopharyngeal head and neck cancers showed no statistical benefit in adding chemotherapy to radiotherapy (RT) in older patients; another meta‐analysis of RT versus chemoradiotherapy (CRT) in NPC found advantages to CRT, but vastly under‐represented patients ≥70 years old. This is the largest study to date evaluating outcomes of CRT versus RT alone in this population. The National Cancer Data Base (NCDB) was queried for primary nasopharyngeal cancer cases (2004–2013) in patients ≥70 years old receiving RT alone or CRT. Patients with unknown RT/chemotherapy and T1N0 or M1 disease were excluded. Logistic regression analysis ascertained factors associated with CRT delivery. Kaplan–Meier analysis evaluated overall survival (OS) between both cohorts. Cox proportional hazards modeling determined variables associated with OS. In total, 930 patients were analyzed (n = 713 (77%) CRT, n = 217 (23%) RT). Groups were relatively balanced; CRT was less frequently delivered in patients with advancing age, lower nodal burden, and females (P < 0.05 for all). Median OS in the CRT and RT groups were 35.3 versus 20.0 months, respectively (P = 0.002). On multivariate analysis, independent predictors of OS included age, comorbidities, income and insurance status, tumor grade, and stage (P < 0.05 for all). Notably, receipt of chemotherapy independently predicted for improved OS (P = 0.036). CRT, compared to RT alone, was independently associated with improved survival in NPC patients ≥70 years old. CRT appears to be a promising approach in this population, but treatment‐related toxicity risks should continue to be weighed against potential oncologic benefits.

show abstract

Section: Discussionsupporting

confidence: 77%

Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…This investigation analyzed the National Cancer Data Base (NCDB), which is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society, which consists of de-identified information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of the US population (11)(12)(13)(14). The NCDB contains information not included in the Surveillance, Epidemiology, and End Results database, including details regarding use of systemic therapy and radiation dose.…”

Section: Methodsmentioning

confidence: 99%

Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base

Haque¹,

Verma

Butler³

et al. 2018

J. Gastrointest. Oncol.

Self Cite

View full text Add to dashboard Cite

Background: Neoadjuvant chemoradiotherapy (CRT) for locally advanced esophageal cancer (EC) may utilize a wide variety of RT doses, without clear consensus to date. This study evaluated national practice patterns between lower dose (LD) (40-41.4 Gy) or higher dose (HD) (50-50.4 Gy) therapy, in addition to differences in survival and postoperative events. Methods: The National Cancer Data Base (NCDB) was queried [2004][2005][2006][2007][2008][2009][2010][2011][2012][2013] for patients with newlydiagnosed cT1a-T4aN0/N+M0 EC that received neoadjuvant CRT followed by esophagectomy. Conclusions: Although neoadjuvant LD CRT has been underutilized for EC in the United States, it is rising in more recent years. Dose did not significantly impact survival before or after propensity matching, nor did it independently predict for survival. Treatment at academic facilities independently correlated with higher survival, which has implications for patient counseling.

show abstract

“…The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society, which consists of deidentified information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of the U.S. population. [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] The NCDB contains information not included in the Surveillance, Epidemiology, and End Results database, including details regarding use of systemic therapy and the dose of radiotherapy (RT). The data used in the study were derived from the deidentified NCDB NPC file (there were no other subsite files utilized).…”

Section: Ate Ri Als An D Me Tho Dsmentioning

confidence: 99%

Human papillomavirus and nasopharyngeal cancer

2018

Self Cite

View full text Add to dashboard Cite

show abstract

Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base

Cited by 35 publications

References 14 publications

Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer

Practice patterns and outcomes of chemoradiotherapy versus radiotherapy alone for older patients with nasopharyngeal cancer

Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base

Human papillomavirus and nasopharyngeal cancer

Contact Info

Product

Resources

About